# TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

> **NCT00415909** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Imatinib Mesylate (IM)
- **DRUG:** TALL-104 cells

## Key facts

- **NCT ID:** NCT00415909
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2014-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415909, "TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00415909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*